Medtronic PLC vs Schwab US Large Cap Growth ETF — how do they compare? Medtronic PLC trades at $88.46 (market cap $112.24B), while Schwab US Large Cap Growth ETF trades at $36.66 (market cap $65.01B). The key difference: Medtronic PLC is the larger of the two by market cap, and Medtronic PLC pays a 3.28% dividend while Schwab US Large Cap Growth ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Medtronic PLC for 63 Days and Schwab US Large Cap Growth ETF for 50 Days on average.
| MDT | SCHG | |
|---|---|---|
Market Cap | $112.24B | $65.01B |
Volume | 105,663,236 | 8,554,399 |
Sector | Health | Sector/Thematic |
52-Week High | $105.35 | $36.93 |
52-Week Low | $73.75 | $28.10 |
Typical Hold Time | 63 Days | 50 Days |
Enterprise Value | $131.58B | — |
Dividend Yield | 3.28% | — |
Signals from Pluang's Aura AI — not financial advice
Medtronic (MDT) trades at $85.51, down 1.81% on the day, with the stock showing bearish technical signals despite strong fundamental performance. The company has beaten earnings expectations for three consecutive quarters, maintains a healthy 13.93% net income margin, and offers a solid 3.2% dividend yield with 49 consecutive years of dividend growth. Recent positive developments include FDA clearances for new medical technologies and raised full-year guidance.
MDT presents a compelling value opportunity with analyst consensus pointing to 14% upside to the $97.80 price target. The stock's current valuation multiples (P/E 21.61, P/S 3.01) appear reasonable given the company's stable revenue growth and strong cash flow generation. Key risks include increasing debt levels and competitive pressures in the medical device sector, but the company's dividend aristocrat status and improving operational performance support a positive long-term outlook.
SCHG (Schwab U.S. Large-Cap Growth ETF) trades at $36.60, down 0.73% on the day, with technical indicators showing a bullish trend supported by moving averages while oscillators remain neutral. The ETF maintains strong institutional interest despite a recent position reduction by Corient Private Wealth. Recent news highlights SCHG's low-cost advantage and growth-focused strategy, though concentration in top holdings presents both opportunity and risk.
The outlook for SCHG remains positive given its exposure to large-cap growth stocks and cost efficiency, though investors should monitor concentration risks in top holdings and broader market volatility. The ETF's historical performance suggests potential for long-term growth, but current valuation levels warrant careful assessment relative to alternatives like GARP strategies.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →SCHG is an ETF that seeks to track the total return of the Dow Jones U.S. Large-Cap Growth Total Stock Market Index. The fund provides low-cost exposure to a diversified portfolio of large-capitalization U.S. companies that are classified as growth stocks based on factors such as sales, earnings, and book value growth rates. SCHG is often used by investors seeking long-term capital appreciation from market-leading companies with above-average growth potential.
Read more on SCHG →